Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the effectiveness and potential side effects of using a minoxidil, finasteride, and biotin combination pill for hair loss, comparing half-dose (0.55mg Fin, 2.5mg Min, 0.5mg Biotin) to full-dose (1.1mg Fin, 5mg Min, 1mg Biotin). The user is considering whether to increase to a full dose after starting with a half dose.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

Experimenting with the effects of creatine and finasteride on DHT levels, as well as a discussion regarding the potential link between creatine supplementation and hair loss.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Alfatradiol is often discussed at a 1% concentration, but studies typically use 0.025%. Some users report success using it as a topical treatment alongside other hair loss treatments like finasteride.

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.

The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.

The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The user improved hair density from 45% to 70% using dutasteride and minoxidil, but still uses hair fibers for a fuller look. They added a topical mix of minoxidil, finasteride, and bimatoprost, but doubt further significant improvement.

The conversation discusses Breezula, a hair loss treatment, and its Phase 3 clinical trial recruitment at 50 locations. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

A user experienced a "watery belly" and cellulite after starting finasteride, despite maintaining a disciplined fitness routine. Others suggest checking hormone levels, as changes in DHT and estrogen could affect fat metabolism, but age might also be a factor.

User creates 0.1% topical finasteride solution using Alfatradiol Avixis base. Seeks help to ensure alfatradiol base dissolves finasteride.

The user has been taking oral Finasteride and topical Essengen 6 Plus for hair loss and is experiencing increased depression. They plan to get bloodwork to check hormone levels and are seeking advice on which tests to include.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

A new light therapy claims to reduce hair loss markers by 92% using a specific wavelength range. Users discuss the cost and effectiveness of devices, with some expressing skepticism and others considering alternative treatments like red light therapy and vitamin D exposure.

Finasteride's effectiveness and side effects may vary based on male phenotypes, with some users noting differences in response related to body and facial hair characteristics. Some users report success with lower doses, while others experience side effects, suggesting individual variability in response to the treatment.

Creating a topical solution combining finasteride and stemoxydine to treat hair loss, and the discussion of whether 15mg of finasteride would be sufficient for 60ml solvent.

OP experienced thicker hair and less shedding with Nutrafol Women’s Balance but had flushing due to ingredients, and is considering switching to Viviscal Pro with saw palmetto. A user shared that Viviscal increased shedding for both him and his girlfriend, and suggested stopping Nutrafol if the hair loss is due to Telogen effluvium.

A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Chris's hair transplant looks better, but the hairline is criticized for being too straight and unnatural. Some recommend using finasteride and minoxidil for maintenance.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

Hair loss discussion focused on 2% Fluridil's peak efficacy at 3 months and 7% Fluridil group buy results, including shedding decrease, side effects, and regrowth.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.